Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Eyepoint Pharmaceuticals Inc is a biotechnology business based in the US. Eyepoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. Eyepoint Pharmaceuticals employs 122 staff and has a trailing 12-month revenue of around $41.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $7.20 |
|---|---|
| 52-week range | $7.00 - $21.50 |
| 50-day moving average | $9.77 |
| 200-day moving average | $10.62 |
| Wall St. target price | $33.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.11 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.2 from 2022-09-23
| 1 week (2022-09-19) | -7.46% |
|---|---|
| 1 month (2022-08-26) | -29.96% |
| 3 months (2022-06-24) | -0.69% |
| 6 months (2022-03-25) | -43.31% |
| 1 year (2021-09-24) | -38.57% |
|---|---|
| 2 years (2020-09-25) | 1,177.28% |
| 3 years (2019-09-26) | 300.00% |
| 5 years (2017-09-26) | 480.65% |
| Revenue TTM | $41.5 million |
|---|---|
| Gross profit TTM | $262,000 |
| Return on assets TTM | -21.49% |
| Return on equity TTM | -59.26% |
| Profit margin | -184.53% |
| Book value | $4.45 |
| Market capitalisation | $265.1 million |
TTM: trailing 12 months
We're not expecting Eyepoint Pharmaceuticals to pay a dividend over the next 12 months.
Eyepoint Pharmaceuticals's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eyepoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Eyepoint Pharmaceuticals shares which in turn could have impacted Eyepoint Pharmaceuticals's share price.
Over the last 12 months, Eyepoint Pharmaceuticals's shares have ranged in value from as little as $6.995 up to $21.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyepoint Pharmaceuticals's is 1.2141. This would suggest that Eyepoint Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
EyePoint Pharmaceuticals, Inc. , a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc. , Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.